Loading...
Loading...
PRTK| Name | Value |
|---|---|
| Revenues | 29.2M |
| Cost of Revenue | 6.2M |
| Gross Profit | 23.0M |
| Operating Expense | 38.8M |
| Operating I/L | -15.8M |
| Other Income/Expense | -4.3M |
| Interest Income | 0.2M |
| Pretax | -20.1M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -20.1M |
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of life-saving therapies for serious diseases. Its lead products include NUZYRA, a broad-spectrum antibiotic for community-acquired bacterial pneumonia and skin infections, and SEYSARA, a treatment for moderate to severe acne vulgaris. The company generates revenue through the sales of these pharmaceutical products, as well as through license and collaboration agreements with other pharmaceutical companies and research institutions for the development and commercialization of various treatments for bacterial and microbial diseases.
